Syncona Ltd - London-based investor in healthcare companies - The US Food & Drug Administration accepts Autolus Therapeutics PLC's biologics licence application for obe-cel for patients with relapsed/refractory adult B-cell acute lymphoblastic leukaemia. The FDA has set a target action date of November 16 for reviewing the application, Syncona says. Further, Autolus is on track to submit a marketing authorisation application to the EU's European Medicines Agency in the first half of 2024.

Syncona has an 18% stake in Autolus.

Current stock price: 117.05 pence, down 0.3% on Monday

12-month change: down 31%

By Tom Budszus, Alliance News slot editor

Comments and questions to

Copyright 2024 Alliance News Ltd. All Rights Reserved.